Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://scienceofmind.com
Are you over 18 and want to see adult content?
A complete backup of https://ketogenicsupplementsreview.com
Are you over 18 and want to see adult content?
A complete backup of https://urban-fairies.com
Are you over 18 and want to see adult content?
A complete backup of https://gumisoftanma.club
Are you over 18 and want to see adult content?
A complete backup of https://orlandobrewing.com
Are you over 18 and want to see adult content?
A complete backup of https://puremagnetik.com
Are you over 18 and want to see adult content?
A complete backup of https://yorkshirelife.co.uk
Are you over 18 and want to see adult content?
A complete backup of https://furmysunshine.com
Are you over 18 and want to see adult content?
A complete backup of https://houkon.jp
Are you over 18 and want to see adult content?
A complete backup of https://estherthewonderpig.com
Are you over 18 and want to see adult content?
A complete backup of https://madhuboats.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of masterskayafanstranic.com.ua
Are you over 18 and want to see adult content?
A complete backup of gardenbythesea.org
Are you over 18 and want to see adult content?
A complete backup of eveningcylinder.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of fashion-flash.de
Are you over 18 and want to see adult content?
A complete backup of ideacellular.com
Are you over 18 and want to see adult content?
A complete backup of driveforloudon.com
Are you over 18 and want to see adult content?
Text
SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets. NEW THERAPIES FOR COVID-19 SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replicationof the virus.
SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results.EVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com RARE DISEASE DAY 2021 Rare Disease Day 2021 - Sombiotech. On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!!SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets. NEW THERAPIES FOR COVID-19 SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replicationof the virus.
SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results.EVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com RARE DISEASE DAY 2021 Rare Disease Day 2021 - Sombiotech. On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!!EVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com RARE DISEASE DAY 2021 Rare Disease Day 2021 - Sombiotech. On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!! SOM BIOTECH IS AWARDED A GRANT FROM CDTI TO START CLINICAL SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency.. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. SOM BIOTECH TO PARTICIPATE AT THE BIO-EUROPE SPRING SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22 nd – 25 th, which will take place digitally due to the pandemic situation.. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma and biotech sectors but also the world´s most AI-BASED DRUG DISCOVERY TECHNOLOGY SOM Biotech closes a remarkable year, achieving relevant advances in its drug development pipeline. Leveraging on its proprietary AI-based drug discovery technology SOM AI-PRO.. According to Raul Insa – CEO of SOM Biotech – “ 2019 has been a great year, in which we have achieved major milestones in our pipeline development.Those achievements prove that our drug discovery strategy SOM BIOTECH AT THE “AI-DRIVEN DRUG REPOSITIONING SOM Biotech will attend the “ AI-Driven Drug Repositioning & Repurposing ” digital congress on April 20 th – 21 st.. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in theSOM BIOTECH
Posted on July 18, 2019. February 9, 2021 by admin. SOM Biotech collaborated in the organization of the University of Barcelona Summer Course: “Rare Diseases: from the patient to the cure”. Within the framework of the course, Dr. Raúl Insa, SOM Biotech CEO, did a master class included in the module “Pharmaceuticals in rare diseases”.SOM BIOTECH
The 2nd Annual Genesis Drug Discovery: “Transforming the Future of Drug Discovery” brings the most innovative event that aims to provide an open and stimulating scientific and cultural exchange that will give all the participants the opportunity to share their experiences, foster collaborations across industry and academia and evaluate emerging technologies across the globe. SOM BIOTECH STRENGTHENS ITS MANAGEMENT TEAM SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead thepipeline
SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets.SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results. SOM BIOTECH IS AWARDED A GRANT FROM CDTI TO START CLINICAL SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency.. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.comEVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com RARE DISEASE DAY 2021 Rare Disease Day 2021 - Sombiotech. On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!!SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets.SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results. SOM BIOTECH IS AWARDED A GRANT FROM CDTI TO START CLINICAL SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency.. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.comEVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com RARE DISEASE DAY 2021 Rare Disease Day 2021 - Sombiotech. On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!!EVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com SOM BIOTECH TO PARTICIPATE AT THE BIO INTERNATIONAL SOM Biotech announces its participation in the BIO International Convention 2021 on June 10 th – 18 th, that will take place digitally.. Hosted by the Biotechnology Innovation Organisation, the event is the largest global event for the biotechnology industry that attracts the leading biotech companies, scientists, research institutions, advisors, and qualified investors, providing extensive RARE DISEASE DAY 2021 Rare Disease Day 2021 - Sombiotech. On the 28th of February, we’ll be celebrating Rare Disease Day 2021. We are proud to work on rare diseases. For SOM Biotech, rare diseases are a challenge that drives us to care for unique people with extraordinary strength. Rare is UNIQUE, rare is EXTRAORDINARY, rare is STRONG!!! SOM BIOTECH IS AWARDED A GRANT FROM CDTI TO START CLINICAL SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency.. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. SOM BIOTECH TO PARTICIPATE AT THE BIO-EUROPE SPRING SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22 nd – 25 th, which will take place digitally due to the pandemic situation.. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma and biotech sectors but also the world´s most SOM BIOTECH TO PARTICIPATE AT THE BIO-EQUITY EUROPE 2021 SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17 th – 19 th, which will take place digitally.. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies as SOM BIOTECH AT THE BIO- PARTNERING JPM VIRTUAL EVENT 2021 SOM Biotech announces its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11 th – 15 th.. The conference, a leading virtual partnering and business development initiative for the biotechnology industry organized by Biotechnology Innovation Organization, provides a One-on-One partnering platform to give companies access to AI-BASED DRUG DISCOVERY TECHNOLOGY SOM Biotech closes a remarkable year, achieving relevant advances in its drug development pipeline. Leveraging on its proprietary AI-based drug discovery technology SOM AI-PRO.. According to Raul Insa – CEO of SOM Biotech – “ 2019 has been a great year, in which we have achieved major milestones in our pipeline development.Those achievements prove that our drug discovery strategy SOM BIOTECH AT THE “AI-DRIVEN DRUG REPOSITIONING SOM Biotech will attend the “ AI-Driven Drug Repositioning & Repurposing ” digital congress on April 20 th – 21 st.. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in the THE FUTURE OF BIOTECHNOLOGY: LOWER-COST TREATMENTS IN A La Vanguardia published a press release: “The future of biotechnology: lower-cost treatments in a short period of time”.. You can find a short overview of the press release below. SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in each project.SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results.SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.comEVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com PHASE 2 CLINICAL RESULTS OF SOM3355 FOR THE TREATMENT OF SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1 st – 4 th 2021.. The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for the poster presentation atSOM BIOTECH
SOM Biotech participated in the Euronext webinar “Finance your tech company´s growth through capital markets” next June 25th. Raul Insa, CEO of SOM Biotech, was a keynote speaker sharing his experience and views on financing alternatives for a biotech company.SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results.SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.comEVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com PHASE 2 CLINICAL RESULTS OF SOM3355 FOR THE TREATMENT OF SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1 st – 4 th 2021.. The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for the poster presentation atSOM BIOTECH
SOM Biotech participated in the Euronext webinar “Finance your tech company´s growth through capital markets” next June 25th. Raul Insa, CEO of SOM Biotech, was a keynote speaker sharing his experience and views on financing alternatives for a biotech company. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com SOM BIOTECH IS AWARDED A GRANT FROM CDTI TO START CLINICAL SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency.. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. SOM BIOTECH TO PARTICIPATE AT THE BIO-EUROPE SPRING SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22 nd – 25 th, which will take place digitally due to the pandemic situation.. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma and biotech sectors but also the world´s most THE FUTURE OF BIOTECHNOLOGY: LOWER-COST TREATMENTS IN A La Vanguardia published a press release: “The future of biotechnology: lower-cost treatments in a short period of time”.. You can find a short overview of the press release below. SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in each project. SOM BIOTECH AT THE “AI-DRIVEN DRUG REPOSITIONING SOM Biotech will attend the “ AI-Driven Drug Repositioning & Repurposing ” digital congress on April 20 th – 21 st.. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in the SOM BIOTECH TO PARTICIPATE AT THE BIO-EQUITY EUROPE 2021 SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17 th – 19 th, which will take place digitally.. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies asSOM BIOTECH
SOM Biotech has been granted SME status as micro-sized enterprise in research and development by the European Medicine Agency (EMA). The main incentives include: fee reductions in regulatory procedures and scientific advice, administrative assistance, and more economical access to various services provided by EMA. AI-BASED DRUG DISCOVERY TECHNOLOGY SOM Biotech closes a remarkable year, achieving relevant advances in its drug development pipeline. Leveraging on its proprietary AI-based drug discovery technology SOM AI-PRO.. According to Raul Insa – CEO of SOM Biotech – “ 2019 has been a great year, in which we have achieved major milestones in our pipeline development.Those achievements prove that our drug discovery strategy SOM BIOTECH STRENGTHENS ITS MANAGEMENT TEAM SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead thepipeline
TERMS OF USE
SOM BIOTECH’s website is aimed at providing information concerning the company and its projects under development. This information is subject to risks and uncertainties and it is presented “AS IS” and there are no assurances with regard to the lack of technical inaccuracies or typographical errors.SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results.SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.comEVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com PHASE 2 CLINICAL RESULTS OF SOM3355 FOR THE TREATMENT OF SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1 st – 4 th 2021.. The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for the poster presentation atSOM BIOTECH
SOM Biotech participated in the Euronext webinar “Finance your tech company´s growth through capital markets” next June 25th. Raul Insa, CEO of SOM Biotech, was a keynote speaker sharing his experience and views on financing alternatives for a biotech company.SOM BIOTECH
May 13, 2021. SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17th – 19th, which will take place digitally. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotechcompanies as
SOM BIOTECH
SOM Biotech wants to act as catalyst to translate orphan disease research into the development of new effective and safe medicines. Founded in 2009, SOM has developed all through the years a unique business model based on the know-how and expertise of talented people, always driven by curiosity, excellence and an instinct ofself-improvement.
OUR TEAM | SOM BIOTECH Our team. Raúl Insa, MD, PhD, MBA FOUNDER, PRESIDENT AND CEO. Catherine Scart, MD CHIEF MEDICAL OFFICER. Kevin McAllister, PhD, MBA CHIEF SCIENTIFIC OFFICER. Saurabh Mishra, MBA CHIEF ANALYTICS OFFICER. Núria Reig, PhD HEAD OF R&D. PARTNERSHIP WITH SOM BIOTECH Find the partnership program with SOM Biotech that’s right for you. Pipeline expansion within any therapeutic area. Life cycle management of existing products to expand opportunities on the market. New targets identification for your shelved assets. Indication expantion for your assets in development. In-licensing of our advanced assets. SOM BIOTECH CONTINUES WORKING TO BRING THERAPIES TO RARE While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in Huntington’s disease in Phase 2 is bringing good results.SOM BIOTECH
If you have any questions, please, contact us, and we will be happy to help. You can find all SOM Biotech contact details on this page. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.comEVENTS - SOMBIOTECH
Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com PHASE 2 CLINICAL RESULTS OF SOM3355 FOR THE TREATMENT OF SOM Biotech will present results from the Phase 2 clinical study of SOM3355 for the treatment of chorea symptoms in Huntington´s disease at the XXVI World Congress on Parkinson’s Disease and Related Disorders, to be held May 1 st – 4 th 2021.. The International Association for Parkinsonism and Related Disorders (IAPRD) has accepted the abstract for the poster presentation atSOM BIOTECH
SOM Biotech participated in the Euronext webinar “Finance your tech company´s growth through capital markets” next June 25th. Raul Insa, CEO of SOM Biotech, was a keynote speaker sharing his experience and views on financing alternatives for a biotech company. INVESTOR INFORMATION Baldiri Reixac, 4 (08028) Barcelona, Spain Phone: +34 934 020 150 Email: info@sombiotech.com SOM BIOTECH IS AWARDED A GRANT FROM CDTI TO START CLINICAL SOM Biotech has been granted €340,000.00 from the Center for Industrial Technological Development (CDTI, Spain), within the extraordinary call for grants for R&D projects to face the COVID-19 health emergency.. With these funds, SOM Biotech will initiate clinical trials for the development of a new eravacycline-based therapy for the treatment of COVID-19. SOM BIOTECH TO PARTICIPATE AT THE BIO-EUROPE SPRING SOM Biotech announces its participation in the BIO-Europe Spring 2021 partnering event on March 22 nd – 25 th, which will take place digitally due to the pandemic situation.. Organized by the EBD Group, a global partnering event organizer, the BIO-Europe Spring event attracts leading decision-makers not only from the traditional pharma and biotech sectors but also the world´s most THE FUTURE OF BIOTECHNOLOGY: LOWER-COST TREATMENTS IN A La Vanguardia published a press release: “The future of biotechnology: lower-cost treatments in a short period of time”.. You can find a short overview of the press release below. SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in each project. SOM BIOTECH AT THE “AI-DRIVEN DRUG REPOSITIONING SOM Biotech will attend the “ AI-Driven Drug Repositioning & Repurposing ” digital congress on April 20 th – 21 st.. Organized by Hanson Wade, the “AI-Driven Drug Repositioning & Repurposing” event aims at featuring real-life case studies and experiences from companies that prove that introducing artificial intelligence in drug repurposing and repositioning is a game-changer in the SOM BIOTECH TO PARTICIPATE AT THE BIO-EQUITY EUROPE 2021 SOM Biotech announces its participation in the BIO-Equity Europe 2021 event on May 17 th – 19 th, which will take place digitally.. Organized by Biocentury and the EBD Group, the BIO-Equity 2021 event attracts leading innovative pharma and biotech companies asSOM BIOTECH
SOM Biotech has been granted SME status as micro-sized enterprise in research and development by the European Medicine Agency (EMA). The main incentives include: fee reductions in regulatory procedures and scientific advice, administrative assistance, and more economical access to various services provided by EMA. AI-BASED DRUG DISCOVERY TECHNOLOGY SOM Biotech closes a remarkable year, achieving relevant advances in its drug development pipeline. Leveraging on its proprietary AI-based drug discovery technology SOM AI-PRO.. According to Raul Insa – CEO of SOM Biotech – “ 2019 has been a great year, in which we have achieved major milestones in our pipeline development.Those achievements prove that our drug discovery strategy SOM BIOTECH STRENGTHENS ITS MANAGEMENT TEAM SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead thepipeline
TERMS OF USE
SOM BIOTECH’s website is aimed at providing information concerning the company and its projects under development. This information is subject to risks and uncertainties and it is presented “AS IS” and there are no assurances with regard to the lack of technical inaccuracies or typographical errors.Skip to content
* About__
* Overview
* Our approach
* Our team
* Pipeline
* Partnership
* News & Events__
* News
* Events calendar
* Contact
* Investors
* __
*
__
* __
ACCELERATED DISCOVERY OF THE THERAPIES APPLYING THE POWER OF ARTIFICIAL INTELLIGENCE AND SCIENTIFICKNOWLEDGE.
WE USE ARTIFICIAL INTELLIGENCE TO BRING THERAPEUTIC SOLUTIONS TO THE PATIENTS WITHOUT A TIME-CONSUMING AND INEFFECTIVE R&D PROCESS. WE ARE TALENTED SCIENTISTS WITH A PASSION FOR INNOVATION.Learn about us
STANDARD DRUG DISCOVERY AND DEVELOPMENT__$1 TO $2 BILLION
Cost of a new drug development10 TO 15 YEARS
To develop a new drug1:10K
Success rate
WE CAN REDUCE THOSE NUMBERS TO$250K – $50M
COST OF A NEW DRUG DEVELOPMENT4 TO 5 YEARS
TO DEVELOP A NEW DRUG3:10
SUCCESS RATE
OUR APPROACH
ARTIFICIAL INTELLIGENCE PROPIETARY DATABASES OF CHEMICAL STRUCTURES SCIENTIFIC EXPERTISE Learn about our Unique Approach OUR DIRECTIONS OF WORK PROPRIETARY PIPELINE7 000
ORPHAN DISEASES
4 000
ORPHAN DISEASES DON’T HAVE TREATMENT THE MAIN FOCUS OF OUR PIPELINE ARE DISEASES WITH ANUNMET MEDICAL NEED.
Learn about our pipeline PROPRIETARY PIPELINE7 000
ORPHAN DISEASES
4 000
ORPHAN DISEASES DON’T HAVE TREATMENT THE MAIN FOCUS OF OUR PIPELINE ARE DISEASES WITH ANUNMET MEDICAL NEED.
Learn about our pipelinePARTNERSHIP
WORKFLOW ADAPTED TO YOUR NEEDS. Learn how you can work with us OUR PERFORMANCE INDICATORS12%
OF OUR PERFORMED PROJECTS HAVE REACHED CLINICAL PHASE 229%
OF OUR PROJECTS HAVE A POSITIVE_IN VITRO_ LEAD
WE COOPERATE WITH
SOM BIOTECH IN THE MEDIA NIPPON CHEMIPHAR AND SOM BIOTECH TO COOPERATE ON NEW, ORPHAN DISEASE INDICATIONS FOR BEVANTOLOL. SOM BIOTECH DISCOVERED DRUG TO FIGHT HUNTINGTON’S DISEASE SOM BIOTECH CLOSES A FINANCING ROUND OF 7M EUROS SOM BIOTECH IS ONE OF THE TOP SPANISH START-UPS TO FOLLOW IN 2020 SOM BIOTECH ACHIEVES RELEVANT ADVANCES IN ITS PIPELINE LEVERAGING ON ITS PROPRIETARY AI-BASED DRUG DISCOVERY TECHNOLOGY SOM BIOTECH ANNOUNCES THE IN VITRO CONFIRMATION OF THREE DRUG CANDIDATES FOR COVID-19LATEST NEWS
THE DESPERATE USE OF DRUGS AGAINST CORONAVIRUS SHOULD BE RATIONALIZED – PRESS RELEASE EL PAÍSMay 12, 2020
SOM Biotech reoriented its capabilities to search for the treatments of COVID-19. Raúl Insa, CEO of SOM Biotech, acknowledges that he had never thought of using his technology to find treatment for infectious disease, but the situation is exceptional. “Our technology works based on chemical structure and we are looking ... ARTIFICIAL INTELLIGENCE IN HEALTHCARE WEBINARMay 8, 2020
Interested in learning more about the role of Artificial Intelligence in Healthcare? Angelo Dalli, AI expert and serial tech entrepreneur, and Raúl Insa, CEO of SOM Biotech, will share their experience and thoughts on this topic at the webinar organized by EBAN – European Business Angels Network. The webinar will ... WE HAVE POSITIONED OURSELVES AS A REFERENCE COMPANY IN DRUG REPOSITIONING – INTERVIEW OF RAÚL INSA FOR “ACTUALIDADECONOMICA”
April 30, 2020
“Actualidad Economica” is the dean magazine of the Spanish economic press, founded in 1958. In the interview with the journal, Raúl tells about SOM Biotech creation, focus, and the objectives of the company. He describes the main development pipeline of SOM Biotech, and outline the expertise of its team. Raúl ... SOM BIOTECH ANNOUNCES IN VITRO CONFIRMATION OF THREE DRUG CANDIDATES FOR COVID-19 IN COLLABORATION WITH THE EWHA WOMANS UNIVERSITYApril 20, 2020
SOM Biotech announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19. The three candidates inhibit the main protease of SARS-CoV-2 and therefore the replication of the virus. Clinical studies with the three candidates can be initiated immediately. SOM Biotech has applied its ... SOM BIOTECH CONTINUES WORKING DURING CORONAVIRUS OUTBREAK TO BRING THERAPIES FOR PATIENTS WITH RARE DISEASES.April 14, 2020
While the coronavirus outbreak grows worldwide, at SOM Biotech we continue working on our pipeline to bring therapies for patients with rare diseases. It is now more important than ever to advance with the support of patients with chronic rare conditions. The development of the SOM3355 program for Chorea in ... SOM BIOTECH STRENGTHENS ITS MANAGEMENT TEAMApril 8, 2020
SOM Biotech strengthens its management team with the appointment of Catherine Scart as Chief Medical Officer and Kevin McAllister as Chief Scientific Officer. Therefore, Catherine Scart MD will join SOM Biotech management team as Chief Medical Officer and will assume responsibility for the company´s clinical trials and lead thepipeline ...
SOM BIOTECH AT THE EYEFORPHARMA BARCELONA VIRTUALMarch 26, 2020
SOM Biotech will attend the Eyeforpharma Barcelona event that will be hosted online due to the impact of COVID-19, between March 31st and April 2nd 2020. Maria Zimina – Business Development Manager – underlines: “We look forward to having the opportunity to share and discuss with potential business partners and ... SOM BIOTECH ENCOURAGES YOU TO STAY AT HOME TO FACE THE COVID-19PANDEMIC
March 18, 2020
At SOM Biotech we want to encourage you to stay at home and protect the most vulnerable people in the face of the COVID-19 pandemic, such as the elderly and those who have chronic and rare diseases with difficult treatment. Like thousands of professionals in the biopharmaceutical and healthcare sector, ...SOM Biotech
Baldiri Reixac, 4 (08028) Barcelona, Spain PHONE: +34 934 020 150 EMAIL: info@sombiotech.comFollow us
Information
Terms of use
Cookies policy
Privacy policy
Subscribe to our newsletter Leave this field empty if you're human: Copyright 2020 © SOM BIOTECH | Designed by Argven__
*
__
* About __
* Overview
* Our approach
* Our team
* Pipeline
* Partnership
* News & Events __
* News
* Events calendar
* Contact
* Investors
__
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. CookiesettingsACCEPT
Privacy & Cookies PolicyClose
PRIVACY OVERVIEW
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities... Necessary Always Enabled Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Non-necessary
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.__
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0